Results 201 to 210 of about 47,533 (300)

Efficacy of Hepatic Artery Infusion Chemotherapy Combined With Regorafenib and Sintilimab Versus Regorafenib Alone in MSS/pMMR Colorectal Cancer Liver Metastases After Second‐Line Treatment Failure

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer liver metastases (CRCLM) have limited treatment options after failure of second‐line systemic therapies. Hepatic artery infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy may offer improved outcomes.
Ran You, Qingyu Xu, Lixing Wang, Bin Leng, Chendong Wang, Zeyu Yu, Ya Lu, Lingfeng Diao, Yi Lu, Guowen Yin   +9 more
wiley   +1 more source

Landscape of splicing factors in early-onset gastric cancer reveals SRSF1 as a key driver of oxaliplatin resistance. [PDF]

J Biol Chem
Zhong B, Xiong Z, Xu H, Zheng J, Mohamed SA, Sun J, Huang D, Deng Z, Guo J, Peng J, Chen Y, Lian L.   +11 more
europepmc   +1 more source

lncRNA MCF2L-AS1/miR-105/ IL-1β Axis Regulates Colorectal Cancer Cell Oxaliplatin Resistance

, 2021
Cai M, Weisheng Hu, C Huang, C Zhou, Li J, Chen Y, Yu Y   +6 more
openalex   +1 more source

Clinical Outcomes of the Alternative GAMMA Regimen in Relapsed Germ Cell Tumours

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Following promising results in a phase II trial evaluating GAMMA as salvage therapy for relapsed germ cell tumours (GCT) who had progressed on cisplatin‐based chemotherapy, the GAMMA regimen was adopted into clinical practice at St Bartholomew's Hospital.
Nasreen Abdul Aziz, Kenrick Ng, Prabhakar Rajan, Jonathan Shamash   +3 more
wiley   +1 more source

OCT2 demethylation cracks open oxaliplatin resistance [PDF]

Nature Reviews Nephrology, 2016
openaire   +1 more source

Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third‐ or Later‐Line Chemotherapy for CLDN18.2‐Positive and HER2‐Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Zolbetuximab is an anti‐claudin18.2 (CLDN18.2) antibody, and the addition of zolbetuximab in combination with fluoropyrimidine and oxaliplatin as a first‐line treatment for CLDN18.2‐positive and HER2‐negative gastric or gastroesophageal junction adenocarcinoma has been shown to improve survival.
Osamu Maeda, Chie Tanaka, Kazuhiro Furukawa, Kazushi Miyata, Dai Shimizu, Shizuki Sugita, Koki Nakanishi, Takashi Hirose, Kazuyuki Mizuno, Fumie Kinoshita, Yachiyo Kuwatsuka, Masahiko Ando, Mitsuro Kanda, Hiroki Kawashima, Yuichi Ando   +14 more
wiley   +1 more source

Fusobacterium nucleatum enhances oxaliplatin resistance in colon cancer by increasing PVT1 expression. [PDF]

J Transl Med
Gao K, Zhang J, Liu C, Yang Y, Wang J, Zhang J, Ma H, Wang F, Zhao L, Wang G.   +9 more
europepmc   +1 more source

Long Non-Coding RNA CBR3-AS1 Promotes Stem-Like Properties and Oxaliplatin Resistance of Colorectal Cancer by Sponging miR-145-5p

, 2020
Liangbao Xie, Guangfei Cui, Tao Li
openalex   +1 more source

Gut Microbiota: A Potential Role in Modulating Carcinogenesis and Response to Anti‐Cancer Therapies

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background The effects of microbiota on cancer are not only limited to their role in oncogenesis, progression and response to anticancer therapies; the disease itself is also influenced by microbiota. In recent investigations, alterations in the gut bacterial community between cancer patients and healthy individuals have been reported ...
Awgichew Shewasinad Yehualashet, Eleni Teklu Fersha, Berhan Begashaw Yikna, Kassahun Dires Ayenew   +3 more
wiley   +1 more source

Data from The RNA-Binding Protein HuR Confers Oxaliplatin Resistance of Colorectal Cancer By Upregulating CDC6

, 2023
Jian Cai, Huaiming Wang, Xiaodong Jiao, Rongkang Huang, Qiyuan Qin, Jianwei Zhang, Honglei Chen, Dan Feng, Xin Tian, Hui Wang   +9 more
openalex   +1 more source